From Pipeline to Payday: The Rare Disease Assets Most Likely to Spark a 2026 M&A Land-Grab

The first half of 2026 marks a high-stakes turning point for the rare disease sector. After years of technical hurdles and regulatory pivots, several high-profile programs in gene editing, RNA interference (RNAi), and novel biologics are nearing the finish line. For investors and patients alike, these readouts represent more than just clinical milestones—they are tests of whether “functional cures” can finally displace lifelong chronic treatments. From the frontlines of CRISPR to the battle for cystic fibrosis dominance, here are the rare disease trials set to move markets this year.

Nephropathy and the “Pipeline-in-a-Product” Rare Disease Race

In the autoimmune space, companies are shifting away from general immunosuppression toward precise B-cell modulation, with the kidney serving as the primary proving ground.

Vertex Pharmaceuticals: Povetacicept (RAINIER)

Vertex is aggressively diversifying beyond its respiratory core by targeting IgA nephropathy (IgAN), a progressive kidney disease. Their candidate, povetacicept, is a dual antagonist of the BAFF and APRIL cytokines, which drive the production of the harmful antibodies that damage the kidneys.

• The Trial: RAINIER (NCT06564142) is a global Phase 3 study involving approximately 480 patients.
• The Stakes: Vertex is looking for a “best-in-class” win. A pre-planned interim analysis of protein reduction (UPCR) at 36 weeks is expected in early 2026. If positive, this could trigger an accelerated approval filing, allowing Vertex to challenge established players. Vertex executives believe the drug has “pipeline-in-a-product” potential for multiple autoimmune conditions.

The CRISPR Milestone: Can Gene Editing Go Mainstream?

While biologics like povetacicept refine how we manage chronic disease, a new wave of CRISPR technologies aims to eliminate the need for management altogether by rewriting the genetic code itself. After a decade of promise, the CRISPR sector is facing its most critical commercial test: can one-time edits actually replace daily pills in the real world?

Intellia Therapeutics: Lonvo-z (HAELO)

As a pioneer in in vivo CRISPR, Intellia is looking to rebound from a depressed share price and regulatory delays in other programs. Their lead candidate for hereditary angioedema (HAE), lonvo-z, aims to permanently knock out the KLKB1 gene to prevent painful swelling attacks.

• The Trial: HAELO (NCT06124625) is a Phase 3 study that completed enrollment in September 2025.
• The Stakes: Topline data is expected by mid-2026. While Intellia’s early data showed a 98% reduction in attacks, the commercial challenge is steep. Lonvo-z must prove to be a “functional cure” to convince patients to abandon effective daily or bi-weekly prophylactics. A win here would be the first-ever Phase 3 validation of an in vivo CRISPR therapy.

Duchenne Muscular Dystrophy: The Next Generation

The Duchenne muscular dystrophy (DMD) market is currently dominated by Sarepta’s Elevidys, but the bar for safety and microdystrophin production remains a point of intense clinical debate. As regulators scrutinize existing treatments, competitors are rushing to prove that “more” protein and “better” delivery can significantly alter the disease’s trajectory.

Regenxbio: RGX-202 (AFFINITY DUCHENNE)

Regenxbio is attempting to leapfrog current treatments by using a larger, more complete microdystrophin protein and a different viral vector (AAV8) designed to improve muscle function.

• The Trial: AFFINITY DUCHENNE (NCT05693142) is a Phase 1/2/3 study measuring protein expression and functional improvement.
• The Stakes: Regenxbio plans a BLA submission in mid-2026. However, interim data has shown results largely in line with Sarepta’s, raising questions about whether RGX-202 can truly differentiate itself. To succeed, the 2026 data must demonstrate a clear functional advantage or a significantly cleaner safety profile than the first generation of gene therapies.

The RNAi Lifeline: Sarepta and Arrowhead

With its core business facing headwinds, Sarepta is leaning heavily on its multi-billion-dollar partnership with Arrowhead Pharmaceuticals to expand into new muscular dystrophies. This strategic shift represents a critical evolution for the company. By leveraging Arrowhead’s Targeted RNAi Molecule (TRiM™) platform, Sarepta aims to move beyond its traditional focus on DMD and address a broader range of genetic neuromuscular diseases that have long lacked effective treatments.

Sarepta & Arrowhead: (SRP-1001 & SRP-1003)

Following a $200 million milestone payment in late 2025, the partners are racing through dose-escalation trials for two debilitating conditions: facioscapulohumeral muscular dystrophy (FSHD) and myotonic dystrophy type 1 (DM1).

• The Trials: NCT06131983 (ARO-DUX4/SRP-1001) and NCT06138743 (ARO-DM1/SRP-1003) are Phase 1/2a studies.
• The Stakes: Topline safety and protein-knockdown results are expected in the first half of 2026. For Sarepta, these “siRNA” candidates represent a vital pivot toward chronic RNA-based treatments. For Arrowhead, success would prove their “TRiM” platform can effectively target skeletal muscle at scale.

Challenging the Giant: The New Front in Cystic Fibrosis

Vertex has long held a monopoly in cystic fibrosis (CF), but Sionna Therapeutics is betting that a new biological target can deliver superior results. By focusing on the stabilization of Nucleotide-Binding Domain 1 (NBD1)—a region of the CFTR protein long considered “undruggable”—Sionna aims to restore protein function to levels that current therapies cannot reach. 

Sionna Therapeutics: (PreciSION CF)

While Vertex’s Trikafta is the gold standard, Sionna claims its “NBD1 stabilizers” can restore even more lung function by fixing the underlying protein defect in a way existing drugs don’t.

• The Trials: PreciSION CF (NCT06077760) and NCT07035990 are Phase 2a and Phase 1 studies evaluating Sionna’s molecules as both add-ons to Trikafta and as a proprietary dual combination.
• The Stakes: Topline data from both trials is anticipated in mid-2026. With a market value nearing $2 billion and over $325 million in cash, Sionna’s future as an independent company—or a prime acquisition target—rests on these results. Investors are looking to see if Sionna can move the needle on sweat chloride levels and lung function (FEV1) beyond what is possible with today’s standard of care.

Market Outlook: The Precision Medicine Surge

The rare disease market is entering a phase of rapid acceleration, with recent forecasts projecting the global orphan drug sector to grow at a CAGR of nearly 12%, reaching $426 billion by 2030. This growth is increasingly fueled by the maturity of RNA-based therapeutics, a sub-sector expected to reach $9.5 billion in 2026 alone. Strategic “price premiums” and the “IRA shield”—which currently exempts certain orphan drugs from Medicare price negotiations—continue to make the rare disease space an attractive haven for R&D investment compared to high-volume chronic markets.

As the industry watches established giants, a new wave of challengers is emerging. Xaira which launched with over $1 billion in April 2024, is leveraging AI models from Nobel Laureate David Baker to design novel proteins for “undruggable” rare targets. Similarly, Actio Biosciences is one to watch in the small-molecule space; their Phase 1 trial for ABS-1230 (KCNT1-related epilepsy) aims to address the root cause of severe genetic seizures where no therapies currently exist. As these newcomers move toward the clinic, the 2026 results from Vertex, Intellia, and Sionna will serve as the bellwether for whether the next decade of biotech belongs to one-time genetic “cures” or highly targeted chronic interventions.

Author

Bernice Lottering